Annual report pursuant to Section 13 and 15(d)

Organization and Summary of Significant Accounting Policies (Details)

v2.4.0.8
Organization and Summary of Significant Accounting Policies (Details) (USD $)
12 Months Ended 12 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Minimum [Member]
Dec. 31, 2013
Maximum [Member]
Dec. 31, 2013
The 1996 Plan [Member]
Dec. 31, 2013
The 2002 Plan [Member]
Dec. 31, 2013
Stock Incentive Plan1996 And2002 [Member]
Dec. 31, 2013
Stock Incentive Plan1996 And2002 [Member]
Minimum [Member]
Dec. 31, 2013
Stock Incentive Plan1996 And2002 [Member]
Maximum [Member]
Dec. 31, 2013
Cira Biosciences Inc [Member]
Dec. 31, 2013
Navidia Biopharmaceuticals Limited [Member]
Jun. 25, 2013
General Electric Capital Corporation [Member]
Dec. 31, 2013
General Electric Capital Corporation [Member]
Dec. 31, 2011
Devicor Medical Products, Inc. [Member]
Dec. 31, 2013
Cardinal Health [Member]
Dec. 31, 2013
BRE/COH LLC [Member]
Organization And Summary Of Accounting Policies [Line Items]                                  
Sales Revenue, Goods, Net, Percentage                             96.00%    
Ownership percentage                     90.00% 100.00%          
Fair value of notes payable $ 29,900,000                                
Shares authorized under share-based compensation plan           1,500,000 12,000,000                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period                 1 year 4 years              
Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term               10 years                  
Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term In Certain Cases               90 days                  
Receivables Percentage                               22.00% 69.00%
Estimated useful lives, property and equipment       3 years 7 years                        
Estimated useful lives, patent costs       5 years 15 years                        
Debt issuance costs     593,000                   881,000 691,000      
Amortization of deferred debt issuance costs 309,000 296,000 2,000                            
Deferred debt issuance costs 691,000 295,000                              
Estimated tax liability from gain on sale of discontinued operation     6,700,000                            
Estimated tax liability from income of discontinued operation     1,200,000                            
Benefit from income taxes $ 0 $ 0 $ 7,880,143